U.S. National Library of Medicine
National Center for Biotechnology Information

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Fondaparinux. [Updated 2020 Nov 16].
Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Fondaparinux

Revised: November 16, 2020.

CASRN: 114870-03-0



Drug Levels and Effects

Summary of Use during Lactation

Fondaparinux is considered to be acceptable to use during breastfeeding.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acenocoumarol, Dalteparin, Enoxaparin, Heparin, Rivaroxaban, Warfarin

References

1. Bates SM, Rajasekhar A, Middeldorp S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: Venous thromboembolism in the context of pregnancy. Blood Adv. 2018;2:3317–59. PubMed PMID: 30482767.

Substance Identification

Substance Name

Fondaparinux

CAS Registry Number

114870-03-0

Drug Class

Breast Feeding

Lactation

Anticoagulants